Comprehensive updated analysis provides valuable evidence on the safety profile of Farxiga, including no imbalance in lower-limb amputations New analyses from CVD-REAL examine reductions in CV events for SGLT-2 inhibitors, including Farxiga in patients with and without CV disease versus DPP-4 inhibitors
AstraZeneca and its global biologics research and development arm, MedImmune, will present the latest research from the Company’s Cardiovascular and Metabolic Diseases (CVMD) therapy area, including for Farxiga (dapagliflozin) and Bydureon(exenatide extended-release), with more than 50 abstracts at the American Diabetes Association’s (ADA) 77th Scientific Sessions in San Diego, USA, 9-13 June 2017
AstraZeneca today announced that it has entered an agreement with Grünenthal for the global rights to Zomig(zolmitriptan) outside Japan
AstraZeneca today presented positive results from its Phase III OlympiAD trial that showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) for patients treated with Lynparza (olaparib) tablets (300mg twice daily), compared to treatment with physician’s choiceof a standard of care chemotherapy.
AstraZeneca, along with its global biologics research and development arm, MedImmune, will demonstrate how it is rapidly delivering on the Company’s science-led strategy for transformational cancer medicine development at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.
AstraZeneca today announced top-line results from the Phase IIIb/IV EXSCEL (EXenatide Study of Cardiovascular Event Lowering) trial.
Results from the Phase III ZONDA trial presented at the American Thoracic Society (ATS) 2017 International Congress demonstrated that adding benralizumab to standard of care allowed patients dependent on OCS to significantly reduce or discontinue steroids while maintaining asthma control.
AstraZeneca announced today that it has entered into an agreement with Recordati S.p.A (Recordati) for the commercial rights to Seloken/Seloken ZOK
AstraZeneca and its global biologics research and development arm, MedImmune, will present new data from its growing respiratory portfolio and pipeline at the 113th annual conference of the American Thoracic Society (ATS) in Washington, DC, USA, 19-24 May 2017
Idag tilldelas Universitetslektor Katalin Dobra, verksam vid Karolinska Institutet och Överläkare vid Karolinska Universitetssjukhuset, Svensk Förening för Patologis (SvFP), stipendie för 2017. Stipendiet uppmärksammar personer som bidrar med betydande insatser inom molekylärpatologisk diagnostik och har instiftats av Svensk Förening för Patologi (SvFP) och AstraZeneca.
Imfinzi met a primary endpoint of statistically-significant and clinically-meaningful progression-free survival (PFS) in ‘all-comer’ patients with locally-advanced, unresectable (Stage III) non-small cell lung cancer in a planned interim analysis
Tralokinumab did not meet its primary endpoint of a significant reduction in the annual asthma exacerbation rate
Second pivotal Phase III trial STRATOS 2 is ongoing with results expected in second half of 2017
AstraZenecaand MedImmune, its global biologics research and development arm, today announced that tralokinumab, an anti-interleukin-13 (IL-13) human monoclonal antibody, did not meet i
Idag tilldelas Överläkare Mikael Johansson, verksam vid Cancercentrum, Norrlands Universitetssjukhus, SLUSG-stipendiet 2017. Stipendiet har instiftats av Svenska Lungcancerstudiegruppen (SLUSG) och AstraZeneca och uppmärksammar personer som bidrar med betydande insatser inom lungcancerområdet.
En positiv start med fortsatt nyhetsflöde kring vår forskningsportfölj i det som har potential att bli ett avgörande år för bolaget
Full approval follows Tagrisso’s expedited Conditional Marketing Authorisation as first-in-class medicine for patients with locally-advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer
Conversion from accelerated to full approval confirms the potential of Tagrissoto become standard of care in the US Approval based on Phase III AURA3 trial thatdemonstrated significant improvement in progression-free survival with Tagrisso as compared to chemotherapy
AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the European Medicines Agency (EMA) has granted orphan designation to inebilizumab (formerly MEDI-551) for the treatment of neuromyelitis optica spectrum disorder (NMOSD).
60 abstracts from early oncology portfolio including 7 oral presentations, across Tumour Drivers and Resistance, Immuno-Oncology, Antibody-Drug Conjugates and DNA Damage Response Potential new medicines targeting cancer cell-death mechanisms highlight potential of emerging Tumour Drivers and Resistance research
First AstraZeneca medicine approved under China’s new Priority Review pathway Tagrisso is an important new medicine in a country where lung cancer is the leading cause of cancer-related deaths and EGFR-mutation rates are among highest globally
Banbrytande data från en internationell observationsstudie av över 300 000 patienter med typ-2 diabetes visar att behandling med SGLT-2-hämmare minskade risken för sjukhusinläggning på grund av hjärtsvikt med 39% och den totala mortaliteten med 51%.